News and Trends 23 Mar 2023 Gut microbiota to be harnessed as a tool to diagnose diseases A recent study at the University of Jyväskylä in Finland compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver. The results revealed that certain microbial metabolites are associated with liver fat content. The fact that the gut microbiota associates with many diseases has raised the hope that they could […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Intracellular “smoke detector” discovery has skin disease therapy implications A study by the University of Bonn in Germany could lead to therapies against skin and intestinal diseases in the medium term.Researchers at the universities of Bonn and Singapore have discovered a new intracellular “smoke detector.” The sensor warns of damage to the mitochondria – the microscopic power plants that supply the cell with energy. […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 LIfT BioSciences hails breakthrough data for treating solid tumors LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly cited by medical professionals as being critical for potentially curing solid tumors in patients. LIfT BioSciences said this involved learning from the experience of other […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Flare Therapeutics sees $123M oncology boost Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has announced a $123 million Series B financing. The financing was co-led by GordonMD Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest […] March 23, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Mar 2023 Hearing loss research: Five advancements in the past year At present, more than 1.4 billion people live with hearing loss globally. Hearing disorders are often caused by aging, frequent exposure to loud noises and even hereditary factors. In this article, we will look at some of the latest advancements in hearing disorders research which could broaden the scope for treatments and other measures to […] March 23, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2023 Etana secures funding for oncology pipeline PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. The round of financing will be used for further strengthening PT Etana Biotechnologies’ pipeline and portfolio especially in oncology. Currently, PT Etana Biotechnologies focuses on local biopharmaceutical production […] March 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2023 5 advancements in Down syndrome research over the past year It was in 1959 when an extra chromosome on the 21st pair in the human cell was discovered by French geneticist Jerome Jean Louis Marie Lejeune. This was followed by research in the discipline of cytogenetics – the study of chromosomes. This chromosomal aberration which affects around one in 1000 live births worldwide, is called […] March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2023 Karuna Therapeutics sees positive schizophrenia trial results Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in positive and negative syndrome scale (PANSS) […] March 21, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2023 Campbell Neurosciences creates saliva-based test for suicidal thoughts Therapeutic Solutions International (TSOI) has announced that its spin-off biotech company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva-based system. Previously, the company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker. In the trial, the company previously assessed levels of the inflammatory marker in 10 […] March 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2023 SpyBiotech receives more than $4 million to develop vaccine platform UK-based SpyBiotech has received a grant of more than $4 million from the Bill & Melinda Gates Foundation to build its SpyVector platform for the development of a cross-protective coronavirus vaccine. The platform, which is based on recombinant adenovirus – a viral vector which can induce cellular immunity – enables a covalent decoration with the […] March 20, 2023 - 2 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 20 Mar 2023 Nine tips to succeed in pharma-biotech partnerships The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration. Here, we’ll go over some expert advice on what to do and what not to do […] March 20, 2023 - 9 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2023 67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival rate at five years, three years after the clinical trials ended. Four out of nine of the patients with newly diagnosed glioblastoma multiforme (GBM) who were part of the clinical study were reported to be alive three years after the […] March 17, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email